- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01262131
Evaluation of Magnetic Fields to Treat Fibromyalgia
June 6, 2011 updated by: pico-tesla Magnetic Therapies, LLC
A Randomized, Double-blind, Placebo-controlled Evaluation of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Fibromyalgia: Pilot Study Protocol
The purpose of this study is to see if a device called the Resonator can help to reduce pain and improve aspects of health and quality of life for people with fibromyalgia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The purpose of this pilot study is to assess the efficacy of the Resonator device as an adjunctive therapy to reducing pain and improving aspects of health and quality of life that are relevant to individuals with fibromyalgia.
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Current diagnosis of fibromyalgia made by the study Principal Investigator (PI) according to the American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia.
- Rating of current Degree of Pain on the 0-10 Numeric Pain Intensity Scale of 4 or greater.
- Subject's use of pain relief medication(s) has been stable over the past 30 days, and subject is willing and able to maintain pre-existing use of pain relief medication(s) as his or her sole pain relief medication use, as needed, throughout study participation.
- Subject's use of insomnia medication(s) has been stable over the past 30 days, and subject is willing and able to maintain this existing use of insomnia medication(s) as his or her sole insomnia relief medication(s), as needed, throughout study participation.
- Subject has been on current (or no) medication regimen, unchanged for at least 30 days prior to study enrollment, and is willing and able to maintain that regular medication regimen, unchanged, throughout study participation.
- Willing and able to refrain from use of tender point injections throughout study participation.
- Willing and able to abstain from partaking in other/new treatments to improve fibromyalgia symptoms during study participation.
- Adequate contraceptive measures for female subjects. > 18 years of age or older.
- Male or female.
Exclusion Criteria:
- Any factors that might prevent the subject from completing a full course of therapy with the Resonator™ device, or from attending any of the scheduled study visits, or from completing any of the study measures.
- Subject suffers from co-existent chronic pain condition(s) of non-fibromyalgia origin, such as osteoarthritis, low back pain, neck pain, painful diabetic neuropathy and postherpetic neuropathic pain, that cannot be distinguished in severity and/or in type/sensation of pain from the pain originating from the subject's condition of fibromyalgia.
- Any other significant comorbidities that might impact the ability to evaluate the subject's satisfaction of the ACR 1990 Criteria for the Classification of Fibromyalgia, or for the subject to complete any of the study assessment tools.
- Tender point injections received within the prior one month.
- Current or past history of major psychiatric disturbance (e.g., schizophrenia, bipolar disorder, substance abuse).
- Known inflammatory rheumatic disease.
- Epilepsy/history of seizures/taking medication for epilepsy.
- HIV and other autoimmune disorders.
- Active cancer or treatment for cancer within last 6 months.
- Active infection(s).
- History of ECT
- Uncontrolled Hypertension.
- Advanced Pulmonary Disease.
- Unstable cardiac disease.
- Prosthetics or implants comprised of ferrous metals.
- Pacemakers, vagus nerve stimulators, or other functional electrical stimulators such as those commonly used for pain.
- Consumption of more than 21 alcoholic drinks per week.
- Pregnant, breast feeding, or planning pregnancy prior to end of study participation.
- Developmental disability or other cognitive impairment that would in the judgment of the PI impair adequate comprehension of the informed consent form or complete any of the study-related activities.
- Worker's compensation, receipt of disability or present/past litigation for monetary compensation pertaining to subject's fibromyalgia condition.
- Participation in other research within 30 days of study enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Resonator Protocol A
|
Application of magnetic fields using the Resonator device Protocol A
|
Active Comparator: Resonator Protocol B
Application of magnetic fields using the Resonator device Protocol B
|
Application of magnetic fields using the Resonator device Protocol B
|
Placebo Comparator: Inactive Resonator
|
Application of inactive magnetic fields using the Resonator device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in 3-recording Average of the Subjects Daily Pain Rating on the 0-10 Numeric Pain Intensity Scale.
Time Frame: 2 weeks (baseline to end of treatment)
|
Minimum scale value is '0' which represents 'no pain at all' and is the best outcome. Maximum scale value is '10 which represents the 'worst pain imaginable' and is the worse outcome. |
2 weeks (baseline to end of treatment)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jerry I Jacobson, Ph.D, D.M.D.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2010
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
May 1, 2011
Study Registration Dates
First Submitted
December 14, 2010
First Submitted That Met QC Criteria
December 16, 2010
First Posted (Estimate)
December 17, 2010
Study Record Updates
Last Update Posted (Estimate)
July 1, 2011
Last Update Submitted That Met QC Criteria
June 6, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10242-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Spaulding Rehabilitation HospitalNot yet recruiting
-
Cairo UniversityNot yet recruiting
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
University of UtahTerminated
-
State University of New York - Upstate Medical...CompletedFibromyalgia, PrimaryUnited States
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
Clinical Trials on magnetic therapy protocol A
-
Cairo UniversityJouf UniversityCompleted
-
Brigham and Women's HospitalNot yet recruiting
-
Royan InstituteTehran University of Medical Sciences; Shahid Beheshti University of Medical...UnknownCovid-19Iran, Islamic Republic of
-
JinyanXingRecruiting
-
The AlfredMonash UniversityRecruitingFibrosis | Lung Diseases | Pancreatic Diseases | Cystic Fibrosis | Genetic Diseases | Respiratory DiseasesAustralia
-
Universidad Complutense de MadridUnknownDiabetic Foot Ulcer | Diabetic Neuropathy PeripheralSpain
-
Balgrist University HospitalUniversity of Zurich, Epidemiology, Biostatistics and Prevention InstituteCompletedBack Pain | Back Pain With Radiation | Back Pain, LowSwitzerland
-
University of Sao PauloRecruitingUrinary IncontinenceBrazil
-
Boston Medical CenterBrigham and Women's HospitalWithdrawnAdhesive Capsulitis
-
Hasan Kalyoncu UniversityCompletedSubacromial Impingement Syndrome | Morphologic ChangeTurkey